Literature DB >> 12098512

High affinity as a disease determinant factor in anti-GM(1) antibodies: comparative characterization of experimentally induced vs. disease-associated antibodies.

P H H Lopez1, A M Villa, R E P Sica, G A Nores.   

Abstract

Elevated titers of serum anti-GM(1) antibodies of IgG isotype are found frequently in patients with Guillain-Barré syndrome. Much evidence indicates that these autoantibodies are involved in disease progression, but their exact function and the mechanism of their appearance are still unclear. In an attempt to reproduce "ganglioside syndrome", the experimental model of neuropathy developed by Nagai et al. (Neurosci. Lett. 2 (1976) 107), rabbits were intensively immunized with GM(1) in complete Freund adjuvant (CFA). High titers of anti-GM(1) antibodies were produced, with class switch and affinity maturation indicating an elaborate immune response. Unexpectedly, the rabbits did not show any clinical symptoms of neuropathy. Relatively affinities of both IgM and IgG antibodies were significantly lower than those of similar antibodies from neuropathy patients. These results suggest the existence of a threshold value above which affinity of anti-GM(1) antibodies becomes an important factor in disease induction. The absence of neuropathy symptoms in rabbits may be explained by absence of these high-affinity anti-GM(1) antibodies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12098512     DOI: 10.1016/s0165-5728(02)00139-x

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

Review 1.  Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.

Authors:  Jens O Watzlawik; Bharath Wootla; Meghan M Painter; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2013-09       Impact factor: 4.618

Review 2.  The origin of anti-GM1 antibodies in neuropathies: the "binding site drift" hypothesis.

Authors:  Pablo H H Lopez; Ricardo D Lardone; Fernando J Irazoqui; Mariana Maccioni; Gustavo A Nores
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

3.  Passive transfer of IgG anti-GM1 antibodies impairs peripheral nerve repair.

Authors:  Pablo H Lopez; Gang Zhang; Jiangyang Zhang; Helmar C Lehmann; John W Griffin; Ronald L Schnaar; Kazim A Sheikh
Journal:  J Neurosci       Date:  2010-07-14       Impact factor: 6.167

4.  Lewis rats immunized with GM1 ganglioside do not develop peripheral neuropathy.

Authors:  Amjad A Ilyas; Zi-Wei Chen
Journal:  J Neuroimmunol       Date:  2007-06-07       Impact factor: 3.478

5.  Normally occurring human anti-GM1 immunoglobulin M antibodies and the immune response to bacteria.

Authors:  María E Alaniz; Ricardo D Lardone; Silvia L Yudowski; María I Farace; Gustavo A Nores
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

6.  Simultaneous measurements of auto-immune and infectious disease specific antibodies using a high throughput multiplexing tool.

Authors:  Atul Asati; Olga Kachurina; Anatoly Kachurin
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

7.  Individual Restriction Of Fine Specificity Variability In Anti-GM1 IgG Antibodies Associated With Guillain-Barré Syndrome.

Authors:  Ricardo D Lardone; Nobuhiro Yuki; Fernando J Irazoqui; Gustavo A Nores
Journal:  Sci Rep       Date:  2016-01-28       Impact factor: 4.379

8.  Affinities of human NMDA receptor autoantibodies: implications for disease mechanisms and clinical diagnostics.

Authors:  Lam-Thanh Ly; Jakob Kreye; Betty Jurek; Jonas Leubner; Franziska Scheibe; Johannes Lemcke; Nina Kerstin Wenke; Sebastian Momsen Reincke; Harald Prüss
Journal:  J Neurol       Date:  2018-09-05       Impact factor: 4.849

9.  Most of anti-glycolipid IgG-antibodies associated to neurological disorders occur without their IgM counterpart.

Authors:  Ricardo Dante Lardone; Fernando José Irazoqui; Gustavo Alejandro Nores
Journal:  J Biomed Sci       Date:  2019-09-06       Impact factor: 8.410

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.